Bexarotene
- Generic Name
- Bexarotene
- Brand Names
- Targretin
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28O2
- CAS Number
- 153559-49-0
- Unique Ingredient Identifier
- A61RXM4375
- Background
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
- Indication
用于全身治疗无效的皮肤Ｔ细胞淋巴癌（CTCL）。
- Associated Conditions
- Refractory Cutaneous T-cell Lymphoma
- Associated Therapies
- -
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
- Conditions
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05296304
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
- Conditions
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 12
- Registration Number
- NCT04664829
- Locations
- 🇸🇬
National Cancer Center Singapore, Singapore, Singapore
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT03323658
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- ReXceptor, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02061878
- Locations
- 🇺🇸
Compass Research, Orlando, Florida, United States
Bexarotene Amyloid Treatment for Alzheimer's Disease
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT01782742
- Locations
- 🇺🇸
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
- Conditions
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01578499
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT01007448
- Locations
- 🇺🇸
Tulane, New Orleans, Louisiana, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Duke University, Durham, North Carolina, United States
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 19
- Registration Number
- NCT01001143
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Preoperative Bexarotene Treatment for Cushing's Disease
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 6
- Registration Number
- NCT00845351
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 10
- Registration Number
- NCT00718770
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.